Table 1.
Clinical, genetic and pathologic characteristics of participants
| Controls (n = 376) |
CTE cases (n = 86) |
P Value | |
|---|---|---|---|
| Age (mean ± SD (range)) | 61.02 ± 10.2 (35–90) | 57.02 ± 21.19 (17–89) | 0.01 |
| Years of exposure (mean ± SD (range)) | – | 13.49 ± 5.47 (1–31) | – |
| Cases with dementia (%) | – | 33 (38.4%) | – |
| TMEM106B MAF | 43.2% | 41.9% | 0.71 |
| rs3173615 genotypes | 0.74 | ||
| CC (%) | 123 (32.7%) | 29 (33.7%) | |
| CG (%) | 181 (48.1%) | 42 (48.8%) | |
| GG (%) | 72 (19.1%) | 15 (17.4%) | |
| CERAD (mean ± SD) | – | 0.29 ± 0.50 | – |
| Cases with TDP-43 (%) | – | 27 (31.4%) | – |
| AT8 Quartiles (positive pixel density/mm2 ± SD) | |||
| 1 | – | 283 ± 221 | |
| 2 | – | 2863 ± 1362 | |
| 3 | – | 10,438 ± 3715 | |
| 4 | – | 65,914 ± 62,629 | |
| CD68 Quartiles (Positive cell/mm2 ± SD) | |||
| 1 | – | 93 ± 15 | |
| 2 | – | 138 ± 10 | |
| 3 | – | 171 ± 10 | |
| 4 | – | 226 ± 31 | |
CERAD Consortium to establish a registry for Alzheimer’s disease, CTE Chronic Traumatic Encephalopathy (Ranges from Stage I-IV), MAF minor allele frequency